@ma420 you don't need a thread on this, I have posted on this before: 1. They aren't both approaching FDA for type C. Travere already had their meeting with FDA, January, and are doing an sNDA application for approval for sparsentan in FSGS 2. Yes they absolutely do have ODD for FSGS (you can google that) 3. Check out my post #77976472. Their commercial partners for the IgA nephropathy indication for sparsentan (CSL-Vifor in Europe, Renalys in Asia) can use the same sales personnel to sell sparsentan to the same customer group (nephrologists) for FSGS as well as IgA nephropathy, it will be easy. Travere as a US company handling US market themselves. Hope that helps.
DXB Price at posting:
43.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)